Enliven Therapeutics, INC

Enliven Therapeutics has priced an upsized public offering of common stock and pre-funded warrants to raise approximately $400 million in gross proceeds.

Enliven Therapeutics announced updated positive Phase 1 data for its CML drug ELVN-001, showing encouraging efficacy and a favorable safety profile, and confirmed alignment with the FDA on Phase 3 trial design.

Enliven Therapeutics announced positive initial Phase 1b data for ELVN-001 in CML patients and a strong cash position extending into the first half of 2029.

Enliven Therapeutics appoints biopharma veteran Scott Garland to its Board of Directors, signaling a strategic shift towards late-stage development and commercialization of its lead asset, ELVN-001.

Enliven Therapeutics announced the appointment of Rick Fair as its new President and CEO, effective December 11, 2025, with co-founder Samuel Kintz transitioning to Head of Pipeline.

Enliven Therapeutics announced its third-quarter 2025 financial results and provided a business update, highlighting progress in its ELVN-001 CML trial and a strong cash position.

Enliven Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $23.6 million and a decrease in R&D expenses, while maintaining a strong cash position.

Enliven Therapeutics reported a reduced net loss in Q3 2025, driven by strategic program prioritization and a strong cash position, while discontinuing ELVN-002 development.

Enliven Therapeutics reports increased losses but secures significant capital through a public offering, extending its cash runway into 2029 while strategically prioritizing its ELVN-001 oncology program.

Enliven Therapeutics reports its financial results for the first quarter ended March 31, 2025, and provides an update on its clinical-stage biopharmaceutical activities, including strategic alternatives for ELVN-002.

Enliven Therapeutics' Q3 2024 report shows increased R&D spending and a net loss, but also highlights a strong cash position and progress in clinical trials.

Enliven Therapeutics reports a net loss of $19.95 million for the second quarter of 2024, with increased spending in research and development.

Enliven Therapeutics' 10-K filing highlights ongoing clinical trials for ELVN-001 and ELVN-002, along with plans for future development and strategic collaborations.

Enliven Therapeutics' 10-K filing details its authorized capital stock, voting rights, and anti-takeover provisions, alongside updates on its clinical programs and financial status.

Benjamin Hohl, CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc., sold 6,018 shares of common stock on July 17, 2026.

Helen Louise Collins, CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc., sold 5,000 shares of common stock on July 17, 2026.

Director Lori Kunkel reported a sale of Enliven Therapeutics, Inc. common stock totaling 10,000 shares, executed under a Rule 10b5-1 trading plan.

OrbiMed Advisors LLC, along with affiliated entities, has reported significant transactions and beneficial ownership changes related to Enliven Therapeutics, Inc. (ELVN).

OrbiMed Advisors LLC reported the sale of 281,408 shares of Enliven Therapeutics, Inc. common stock at a price of $45.02 per share.

Enliven Therapeutics Director Lori Kunkel sold 10,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to address key corporate proposals including director elections and a significant increase in authorized shares.

Enliven Therapeutics will hold its annual stockholders meeting virtually on June 24, 2025, to elect directors and ratify the appointment of its accounting firm.

Enliven Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 24, 2025, featuring director elections and ratification of the company's independent auditor.

Enliven Therapeutics will hold its annual stockholders meeting on June 18, 2024, to vote on the election of directors, ratification of the auditor, and amendments to the certificate of incorporation and equity incentive plan.

Enliven Therapeutics will conduct its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, to vote on director elections, auditor ratification, officer liability limitation, and an equity incentive plan amendment.

OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics, Inc. by more than 1%.

OrbiMed Advisors filed an amendment to its Schedule 13D reporting a change in beneficial ownership of Enliven Therapeutics, Inc. common stock.

OrbiMed Advisors and its affiliated entities have updated their Schedule 13D filing, reporting a reduced percentage ownership in Enliven Therapeutics, Inc. due to the company's recent public offering.

Polar Capital Holdings Plc has filed a Schedule 13G reporting an 8.46% beneficial ownership stake in Enliven Therapeutics, Inc.

Vestal Point Capital, LP and Ryan Wilder have disclosed a passive 5.4% beneficial ownership stake in Enliven Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates report a 2.8% beneficial ownership stake in Enliven Therapeutics, Inc.

Commodore Capital LP and its principals have reported a 7.7% beneficial ownership stake in Enliven Therapeutics, Inc. as of March 31, 2026.

Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported a beneficial ownership of 8.47% in Enliven Therapeutics, Inc.

A group of Venrock entities and individuals reported a continued beneficial ownership of 5.4% in Enliven Therapeutics, Inc. as of September 30, 2025.